Maternal serum midkine level increases in pregnant women with diabetes mellitus: a case-control study

Oluklu D., Beser D. M., Hendem D. U., Sinaci S., Turgut E., YAZIHAN N., ...Daha Fazla

GYNECOLOGICAL ENDOCRINOLOGY, cilt.38, sa.4, ss.329-332, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1080/09513590.2022.2045937
  • Dergi Adı: GYNECOLOGICAL ENDOCRINOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.329-332
  • Anahtar Kelimeler: Midkine, diabetic pregnancy, gestational diabetes mellitus, preexisting diabetes mellitus, perinatal outcomes
  • Ankara Üniversitesi Adresli: Evet

Özet

Objective We aimed to compare maternal serum midkine level in pregnant women with different types of diabetes mellitus (DM) and healthy pregnant women. We also assessed maternal serum midkine level performance to predict adverse neonatal outcomes in the DM group. Methods The study included 57 pregnant women diagnosed with gestational diabetes mellitus (GDM) and 41 pregnant women with preexisting DMThe control group consisted of 98 healthy pregnant women. Results Serum midkine level is higher in the DM group than healthy ones (0.93 +/- 0.8 vs. 0.23 +/- 0.2, p<.001). When the diabetic groups were compared, the highest serum midkine level was found in GDM, followed by Type 1 DM and Type 2 DM (1.33 +/- 0.9 ng/ml, 0.58 +/- 0.5 ng/ml vs. 0.30 +/- 0.2, respectively). Maternal serum midkine level was higher in the DM group with adverse perinatal outcomes than those without adverse outcomes, but there was no statistical difference (0.97 +/- 0.91vs. 0.87 +/- 0.73, p=.571). Conclusions Serum midkine level was significantly higher in pregnant women with GDM, Type 1, and 2 DM than healthy ones. Serum midkine level did not predict adverse neonatal outcomes in the DM group.